Shire defends high prices of orphan drugs
This article was originally published in Scrip
Shire has defended the high prices charged for orphan drugs, claiming that while the costs of developing an orphan drug may be the same as developing any other drug, the capital costs associated with orphan drug development are "not so obvious", and the challenges to development are more numerous.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.